ArticleWellcome open research2022

LEISH2b - A phase 2b study to assess the safety, efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis.

Charles Lacey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.